Abbott ADR Reporting Cited In FDA Warning Letter On Meridia, Norvir, Biaxin
Executive Summary
Abbott expects that continued improvements to its Adverse Event Global Information System (AEGIS) will address ADR reporting problems cited in an 1FDA warning letter
You may also be interested in...
Will A CV Warning On Meridia Alter FDA Views On Obesity Drugs?
The FDA's cardiovascular safety warning on Abbott's obesity drug Meridia (sibutramine) - which was issued in light of early results from a 10,000 patient strong outcomes study - could mean higher regulatory risk for up-and-coming obesity drugs
Will A CV Warning On Meridia Alter FDA Views On Obesity Drugs?
The FDA's cardiovascular safety warning on Abbott's obesity drug Meridia (sibutramine) - which was issued in light of early results from a 10,000 patient strong outcomes study - could mean higher regulatory risk for up-and-coming obesity drugs
Foreign Safety Data Sought By FDA Under Proposed Rule On Periodic Updates
FDA's safety reporting rule would require drug and biologic sponsors to review any safety information acquired from a foreign regulatory authority to determine whether it should be reported to the agency